SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics Monthly Activity About

SEC Comment Letter for Hyperfine, (HYPR) — Jan 28, 2022

Hyperfine, Inc.
Date: Jan. 28, 2022 · CIK: 0001833769 · Accession: 0000000000-22-001152

AI Filing Summary & Sentiment

File numbers found in text: 333-262300

Date
January 28, 2022
Author
Not clearly detected
Form
UPLOAD
Company
Hyperfine, Inc.

Letter

United States securities and exchange commission logo January 28, 2022 Neela Paykel General Counsel and Corporate Secretary Hyperfine, Inc. 351 New Whitfield Street Guilford, Connecticut 06437 Re:Hyperfine, Inc. Registration Statement on Form S-1 Filed January 24, 2022 File No. 333-262300 Dear Ms. Paykel: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jessica Ansart at (202) 551-4511 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: John Condon

Show Raw Text
United States securities and exchange commission logo
January 28, 2022
Neela Paykel
General Counsel and Corporate Secretary
Hyperfine, Inc.
351 New Whitfield Street
Guilford, Connecticut 06437
Re:Hyperfine, Inc.
Registration Statement on Form S-1
Filed January 24, 2022
File No. 333-262300
Dear Ms. Paykel:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Jessica Ansart at (202) 551-4511 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       John Condon